| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Lexeo Therapeutics IncLXEO | $3.23 | Strong Buy | $37.00 | +1,045.51% | a day ago | |
Analyst RankingTop 3% #135 out of 5561 analysts Average Return+23.56% Win Rate41%107 out of 264 Risk vs RewardPoor Good Analyst ColorCantor Fitzgerald's Kristen Kluska raised their price target on Lexeo Therapeutics (NASDAQ: LXEO) by 60.9% from $23 to $37 on 2026/11/16. The analyst maintained their Strong Buy rating on the stock. Raising their price target on Lexeo Therapeutics, Kluska referenced Phase 1/2 interim data for LX2020 for PKP2 arrthymogenic cardiomyopathy, headlining that the data evidence a meaningful improvement from 2026/01, with broad effects observed throughout, including non-sustained ventricular tachycardia. The analyst said they now have a much higher conviction in the program. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | 2 days ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to Premium? Sign In | ||||||